In a report released today, Geoff Meacham from Bank of America Securities reiterated a Buy rating on Sana Biotechnology (SANA – Research Report), with a price target of $14.00. The company’s shares opened today at $7.67.
Meacham covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Eli Lilly & Co, and Moderna. According to TipRanks, Meacham has an average return of 3.0% and a 49.46% success rate on recommended stocks.
Sana Biotechnology has an analyst consensus of Strong Buy, with a price target consensus of $12.25, representing a 59.71% upside. In a report released on May 9, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.
Based on Sana Biotechnology’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $88.12 million. In comparison, last year the company had a GAAP net loss of $80.44 million
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SANA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sana Biotechnology (SANA) Company Description:
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases.
